Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme

JAMA Dermatol. 2018 Apr 1;154(4):487-489. doi: 10.1001/jamadermatol.2017.5889.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Chronic Disease
  • Drug Substitution
  • Erythema Multiforme / drug therapy*
  • Female
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Recurrence
  • Thalidomide / adverse effects

Substances

  • Immunologic Factors
  • Thalidomide
  • Lenalidomide